DT09 Reciper PCT/PTO n 9 DEC 2004 Complete if Known **Application Number** National Entry of PCT/EP03/06591 INFORMATION DISCLOSURE Herewith 10/517330 Filing Date STATEMENT BY APPLICANT First Named Inventor Sven Ole WARNAAR et al Group Art Unit Examiner Name Sheet of Attorney Docket Number 2923-672 NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), T² Initials\* No.1 publisher, city and/or country where published Beck Joachim et al., "A Phase I/II trial with monoclonal antibody WX-G250 in combination with low dose interleukin-2 in metastatic renal cell carcinoma", PROCEEDINGS OF THE AMERICA ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 43, March 2002, pg. Bleumer I et al., "A phase II trial with monoclonal antibody WX-G250 in advanced renal cell carcinoma", EUROPEAN UROLOGY SUPPLEMENTS, vol. 1, no. 1, January 2002, pg. 112. Liu Zhangi et al., "Anti-renal cell carcinoma chimeric antibody G250: Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 51, no. 3, May 2002, pgs. 171-177. Van Dijk J. et al., "Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts", INTERNATIONAL JOURNAL OF CANCER, vol. 56, no. 2, 1994, pgs. 262-268. Varga Z et al., "A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients", FOLIA BIOLOGICA, vol. 49, no. 2, 2003, pgs. 74-77. Bleumer Ivar et al., "A phase I/II trial with chimeric monoclonal antibody WX-G250 in combination with low-dose interlegkin-2 for patients with metastatic renal cell carcinoma", JOURNAL OF UROLOGY, vol. 169, no. 4 Supplement, April 2003, pg. 261. Date Examiner

\*EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Vhow

Signature

Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.